Dipeptidyl peptidase IV inhibitors and ischemic myocardial injury

Alyssa H. Yoon, Yumei Ye, Yochai Birnbaum

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Diabetes mellitus is a major risk factor for cardiovascular events and patient death. Many animal and clinical studies are now being conducted exploring the potential of antidiabetic drugs such as glucagon-like peptide 1 (GLP-1) agonists and dipeptidyl peptidase IV (DPP-IV) inhibitors to improve cardiovascular outcomes. This review summarizes the effect of DPP-IV inhibitors on myocardial ischemia-reperfusion injury in animal models. The DPP-IV inhibitors prevent the rapid degradation and inactivation of incretins and lead to the accumulation of GLP-1 and other chemokines and cytokines, which appear to have both GLP-1 receptor-dependent and -independent cardioprotective, antiapoptotic, and anti-inflammatory effects. Conflicting results, however, have been reported regarding the effect of DPP-IV inhibitors on infarct size in nondiabetic and diabetic animal models. Some studies suggest that DPP-IV inhibitors given as part of preconditioning can decrease infarct size while others found no difference in infarct size compared to placebo. As postconditioning, one study suggested it does provide cardioprotection. No clinical trials have yet been conducted addressing the effect of DPP-IV inhibitors on infarct size. Thus far, clinical trials have not demonstrated improvement in cardiovascular events or mortality from any cause in high cardiovascular risk, type 2 diabetic patients with the use of DPP-IV inhibitors. Although further experiments and clinical trials will be warranted to confirm the results of these studies, the myocardial protection afforded by DPP-IV inhibitors in preclinical animal studies poses a potential breakthrough role for antidiabetic medications in attenuation of ischemia-reperfusion injury that occurs with cardiovascular disease.

Original languageEnglish (US)
Pages (from-to)417-425
Number of pages9
JournalJournal of Cardiovascular Pharmacology and Therapeutics
Volume19
Issue number5
DOIs
StatePublished - 2014

Fingerprint

Dipeptidyl-Peptidase IV Inhibitors
Wounds and Injuries
Glucagon-Like Peptide 1
Clinical Trials
Reperfusion Injury
Hypoglycemic Agents
Animal Models
Incretins
Myocardial Reperfusion Injury
Chemokines
Myocardial Ischemia
Diabetes Mellitus
Anti-Inflammatory Agents
Cardiovascular Diseases
Placebos
Cytokines
Mortality

Keywords

  • Diabetes mellitus
  • Dipeptidyl peptidase inhibitors
  • Glucagon-like peptide 1
  • Infarct
  • Ischemia-reperfusion

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Cardiology and Cardiovascular Medicine

Cite this

Dipeptidyl peptidase IV inhibitors and ischemic myocardial injury. / Yoon, Alyssa H.; Ye, Yumei; Birnbaum, Yochai.

In: Journal of Cardiovascular Pharmacology and Therapeutics, Vol. 19, No. 5, 2014, p. 417-425.

Research output: Contribution to journalArticle

@article{71bc4a2dd1d4490f8e3a6b3f18f6d1d4,
title = "Dipeptidyl peptidase IV inhibitors and ischemic myocardial injury",
abstract = "Diabetes mellitus is a major risk factor for cardiovascular events and patient death. Many animal and clinical studies are now being conducted exploring the potential of antidiabetic drugs such as glucagon-like peptide 1 (GLP-1) agonists and dipeptidyl peptidase IV (DPP-IV) inhibitors to improve cardiovascular outcomes. This review summarizes the effect of DPP-IV inhibitors on myocardial ischemia-reperfusion injury in animal models. The DPP-IV inhibitors prevent the rapid degradation and inactivation of incretins and lead to the accumulation of GLP-1 and other chemokines and cytokines, which appear to have both GLP-1 receptor-dependent and -independent cardioprotective, antiapoptotic, and anti-inflammatory effects. Conflicting results, however, have been reported regarding the effect of DPP-IV inhibitors on infarct size in nondiabetic and diabetic animal models. Some studies suggest that DPP-IV inhibitors given as part of preconditioning can decrease infarct size while others found no difference in infarct size compared to placebo. As postconditioning, one study suggested it does provide cardioprotection. No clinical trials have yet been conducted addressing the effect of DPP-IV inhibitors on infarct size. Thus far, clinical trials have not demonstrated improvement in cardiovascular events or mortality from any cause in high cardiovascular risk, type 2 diabetic patients with the use of DPP-IV inhibitors. Although further experiments and clinical trials will be warranted to confirm the results of these studies, the myocardial protection afforded by DPP-IV inhibitors in preclinical animal studies poses a potential breakthrough role for antidiabetic medications in attenuation of ischemia-reperfusion injury that occurs with cardiovascular disease.",
keywords = "Diabetes mellitus, Dipeptidyl peptidase inhibitors, Glucagon-like peptide 1, Infarct, Ischemia-reperfusion",
author = "Yoon, {Alyssa H.} and Yumei Ye and Yochai Birnbaum",
year = "2014",
doi = "10.1177/1074248414524482",
language = "English (US)",
volume = "19",
pages = "417--425",
journal = "Journal of Cardiovascular Pharmacology and Therapeutics",
issn = "1074-2484",
publisher = "SAGE Publications Ltd",
number = "5",

}

TY - JOUR

T1 - Dipeptidyl peptidase IV inhibitors and ischemic myocardial injury

AU - Yoon, Alyssa H.

AU - Ye, Yumei

AU - Birnbaum, Yochai

PY - 2014

Y1 - 2014

N2 - Diabetes mellitus is a major risk factor for cardiovascular events and patient death. Many animal and clinical studies are now being conducted exploring the potential of antidiabetic drugs such as glucagon-like peptide 1 (GLP-1) agonists and dipeptidyl peptidase IV (DPP-IV) inhibitors to improve cardiovascular outcomes. This review summarizes the effect of DPP-IV inhibitors on myocardial ischemia-reperfusion injury in animal models. The DPP-IV inhibitors prevent the rapid degradation and inactivation of incretins and lead to the accumulation of GLP-1 and other chemokines and cytokines, which appear to have both GLP-1 receptor-dependent and -independent cardioprotective, antiapoptotic, and anti-inflammatory effects. Conflicting results, however, have been reported regarding the effect of DPP-IV inhibitors on infarct size in nondiabetic and diabetic animal models. Some studies suggest that DPP-IV inhibitors given as part of preconditioning can decrease infarct size while others found no difference in infarct size compared to placebo. As postconditioning, one study suggested it does provide cardioprotection. No clinical trials have yet been conducted addressing the effect of DPP-IV inhibitors on infarct size. Thus far, clinical trials have not demonstrated improvement in cardiovascular events or mortality from any cause in high cardiovascular risk, type 2 diabetic patients with the use of DPP-IV inhibitors. Although further experiments and clinical trials will be warranted to confirm the results of these studies, the myocardial protection afforded by DPP-IV inhibitors in preclinical animal studies poses a potential breakthrough role for antidiabetic medications in attenuation of ischemia-reperfusion injury that occurs with cardiovascular disease.

AB - Diabetes mellitus is a major risk factor for cardiovascular events and patient death. Many animal and clinical studies are now being conducted exploring the potential of antidiabetic drugs such as glucagon-like peptide 1 (GLP-1) agonists and dipeptidyl peptidase IV (DPP-IV) inhibitors to improve cardiovascular outcomes. This review summarizes the effect of DPP-IV inhibitors on myocardial ischemia-reperfusion injury in animal models. The DPP-IV inhibitors prevent the rapid degradation and inactivation of incretins and lead to the accumulation of GLP-1 and other chemokines and cytokines, which appear to have both GLP-1 receptor-dependent and -independent cardioprotective, antiapoptotic, and anti-inflammatory effects. Conflicting results, however, have been reported regarding the effect of DPP-IV inhibitors on infarct size in nondiabetic and diabetic animal models. Some studies suggest that DPP-IV inhibitors given as part of preconditioning can decrease infarct size while others found no difference in infarct size compared to placebo. As postconditioning, one study suggested it does provide cardioprotection. No clinical trials have yet been conducted addressing the effect of DPP-IV inhibitors on infarct size. Thus far, clinical trials have not demonstrated improvement in cardiovascular events or mortality from any cause in high cardiovascular risk, type 2 diabetic patients with the use of DPP-IV inhibitors. Although further experiments and clinical trials will be warranted to confirm the results of these studies, the myocardial protection afforded by DPP-IV inhibitors in preclinical animal studies poses a potential breakthrough role for antidiabetic medications in attenuation of ischemia-reperfusion injury that occurs with cardiovascular disease.

KW - Diabetes mellitus

KW - Dipeptidyl peptidase inhibitors

KW - Glucagon-like peptide 1

KW - Infarct

KW - Ischemia-reperfusion

UR - http://www.scopus.com/inward/record.url?scp=84928169199&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84928169199&partnerID=8YFLogxK

U2 - 10.1177/1074248414524482

DO - 10.1177/1074248414524482

M3 - Article

VL - 19

SP - 417

EP - 425

JO - Journal of Cardiovascular Pharmacology and Therapeutics

JF - Journal of Cardiovascular Pharmacology and Therapeutics

SN - 1074-2484

IS - 5

ER -